- Home
- ANAB vs PGY Comparison
ANAB vs PGY Comparison
Compare ANAB & PGY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- PGY
- Stock Information
- Founded
- ANAB 2005
- PGY 2016
- Country
- ANAB United States
- PGY United States
- Employees
- ANAB N/A
- PGY N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- PGY Finance: Consumer Services
- Sector
- ANAB Health Care
- PGY Finance
- Exchange
- ANAB Nasdaq
- PGY Nasdaq
- Market Cap
- ANAB 759.5M
- PGY 870.4M
- IPO Year
- ANAB 2017
- PGY N/A
- Fundamental
- Price
- ANAB $18.40
- PGY $10.56
- Analyst Decision
- ANAB Buy
- PGY Strong Buy
- Analyst Count
- ANAB 10
- PGY 9
- Target Price
- ANAB $36.38
- PGY $21.61
- AVG Volume (30 Days)
- ANAB 907.9K
- PGY 1.6M
- Earning Date
- ANAB 05-08-2025
- PGY 05-08-2025
- Dividend Yield
- ANAB N/A
- PGY N/A
- EPS Growth
- ANAB N/A
- PGY N/A
- EPS
- ANAB N/A
- PGY N/A
- Revenue
- ANAB $91,280,000.00
- PGY $1,032,248,000.00
- Revenue This Year
- ANAB N/A
- PGY $16.25
- Revenue Next Year
- ANAB $59.43
- PGY $14.08
- P/E Ratio
- ANAB N/A
- PGY N/A
- Revenue Growth
- ANAB 432.03
- PGY 27.12
- 52 Week Low
- ANAB $12.21
- PGY $8.20
- 52 Week High
- ANAB $41.31
- PGY $19.20
- Technical
- Relative Strength Index (RSI)
- ANAB 55.72
- PGY 43.87
- Support Level
- ANAB $17.50
- PGY $9.95
- Resistance Level
- ANAB $19.60
- PGY $12.70
- Average True Range (ATR)
- ANAB 1.34
- PGY 0.72
- MACD
- ANAB 0.16
- PGY -0.06
- Stochastic Oscillator
- ANAB 57.04
- PGY 34.15
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About PGY Pagaya Technologies Ltd.
Pagaya Technologies Ltd is a financial technology company working to reshape the lending marketplace by using machine learning, data analytics, and sophisticated AI-driven credit and analysis technology. It was built to provide a comprehensive solution to enable the credit industry to deliver customers a positive experience while simultaneously enhancing the broader credit ecosystem. Its proprietary API seamlessly integrates into its next-gen infrastructure network of partners to deliver a premium customer user experience and greater access to credit. The company generates majority of its revenue from United States.